3544-47-6

Basic information

• Product Name: 2-CHLORO-5-METHANESULFONYL-BENZENESULFONAMIDE
• Synonyms: 2-CHLORO-5-METHANESULFONYL-BENZENESULFONAMIDE;2-chloro-5-methylsulfonylbenzenesulfonamide
• CAS NO: 3544-47-6
• Molecular Formula: C₇H₈ClNO₄S₂
• Molecular Weight: 269.72572
• Mol File: 3544-47-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 534.9°C at 760 mmHg
• Flash Point: 277.3°C
• Appearance: /
• Density: 1.567g/cm³
• Vapor Pressure: 1.62E-11mmHg at 25°C
• Refractive Index: 1.582
• CAS DataBase Reference: 2-CHLORO-5-METHANESULFONYL-BENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5-METHANESULFONYL-BENZENESULFONAMIDE(3544-47-6)
• EPA Substance Registry System: 2-CHLORO-5-METHANESULFONYL-BENZENESULFONAMIDE(3544-47-6)

Safety Data

• Hazardous Substances Data: 3544-47-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H8ClNO4S2/c1-14(10,11)5-2-3-6(8)7(4-5)15(9,12)13/h2-4H,1H3,(H2,9,12,13)

Upstream product

• 90084-62-1 2-chloro-5-methanesulfonyl-benzenesulfonyl chloride 
• 16328-56-6 1-amino-2-chloro-5-methylsulfonylbenzene 
• 98-57-7 4-chlorophenyl methyl sulfone 

Downstream Products

• 7409-84-9 2-amino-5-(methylsulfonyl)benzenesulfonamide 
• 1429321-56-1 C₁₄H₁₂N₂O₄S₃ 
• 1429321-57-2 C₁₆H₁₆N₂O₄S₃ 
• 852675-21-9 R/S-N-(2-amino-5-methylsulfonylbenzenesulfonyl)-N'-2-butylthiourea 
• 852675-20-8 N-(2-amino-5-methylsulfonylbenzenesulfonyl)-N'-isopropylthiourea 
• 852675-19-5 N-(2-amino-5-methylsulfonylbenzenesulfonyl)-N'-ethylthiourea 

Relevant articles and documents

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS

The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (ΤΡβ) receptor subtype.

Effect on KATP channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides

The present work explored 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides diversely substituted in the 7-position. Those compounds, structurally related to previously described potassium channel openers such as the benzothiadiazine dioxide BPDZ 73, we